Apolipoprotein Scaffold–Interface Coupling in Classical Lipoprotein Identity and Routing

1. Introduction

Classical plasma lipoprotein biology is organized around well-established particle classes defined primarily by hydrated density, size, lipid composition, and apolipoprotein content [1]. Chylomicrons and very-low-density lipoproteins are triglyceride-rich lipoproteins that transport dietary and hepatically derived triglycerides, respectively [2], whereas low-density lipoproteins constitute the major cholesterol-rich apoB-containing particles and deliver cholesterol to cells through receptor-mediated uptake [3]. High-density lipoproteins mediate cellular cholesterol efflux and undergo continuous intravascular remodeling through the coordinated actions of lipid-transfer proteins, esterifying enzymes, and lipases [4]. Together with extensive genetic and clinical investigation, these structural and biochemical frameworks have made plasma lipoprotein metabolism one of the most mature areas of extracellular lipid biology [1,3,5].

A mechanistic gap nevertheless remains between bulk lipid composition and biologically operative particle identity. To function as a circulating lipoprotein, an extracellular lipid-bearing assembly must present an aqueous-compatible amphipathic surface, maintain sufficient structural stability, incorporate or retain an appropriate apolipoprotein scaffold, and interact productively with remodeling enzymes, receptors, and clearance pathways [6,7]. Even particles assigned to the same nominal lipoprotein class—or carrying similar amounts of bulk cholesterol, triglycerides, or major apolipoproteins—can differ in oxidative modification, sphingolipid and phospholipid composition, lipid packing, surface charge, associated proteins, and biological activity [8,9,10,11]. Such differences are conventionally described as subclass heterogeneity, compositional remodeling, or lipoprotein dysfunction. However, class assignment and bulk compositional measurements do not by themselves determine whether the organization of the particle interface contributes causally to its interactions and biological behavior [10,11,12].

The present article proposes a mechanistic, rather than taxonomic, extension of lipoprotein biology. Classical lipoproteins are treated here as apolipoprotein-scaffolded lipid-state particles, consistent with the established structural roles of apoB and exchangeable apolipoproteins in stabilizing lipid assemblies and directing their metabolic interactions [6,7]. The term does not replace low-density lipoprotein, high-density lipoprotein, or any other established particle designation, nor does it imply the existence of an unknown category of extracellular particles. Instead, it asks whether measurable organization of the lipid interface, acting cooperatively with apolipoprotein scaffolds, exchangeable apolipoproteins, and other particle-associated plasma proteins, contributes to variation in particle stability, metabolic routing, and function that is not fully represented by particle abundance, bulk lipid mass, apolipoprotein concentration, or canonical receptor assignments alone [7,9,11,12,13].

This proposition is medically relevant because routine clinical lipid assessment primarily quantifies concentrations of total, low-density lipoprotein, and high-density lipoprotein cholesterol and triglycerides, while apoB and apoA-I may be measured as additional variables in selected clinical or research settings [14]. Yet inflammatory and metabolic disorders can remodel lipoprotein composition and function in ways that are not fully represented by these bulk measures [11,12,15]. Cholestatic disorders provide a particularly instructive example, because they can generate compositionally and metabolically distinct lipoprotein-X particles whose cholesterol content and apparent density can confound interpretation based on conventional lipid measurements alone [16,17]. A state-resolved model would therefore be justified only if it improves mechanistic interpretation or prediction beyond established lipoprotein variables.

2. The Hypothesis

2.1. Operational Definition of Lipid-Interface State

A lipid-interface state is defined here as a measurable, perturbable, and temporally persistent organization of lipids within a particle that alters—or is hypothesized to alter—protein recruitment, membrane interaction, receptor engagement, enzymatic remodeling, clearance, or recipient-cell response. It is therefore not synonymous with any lipidomic difference. Candidate, experimentally tractable dimensions include molecular composition and covalent modification; curvature, lipid packing, interfacial hydration, electrostatic properties, phase organization, and cholesterol accessibility; topological exposure of individual lipid species; and coupling to apolipoproteins or other particle-associated proteins [6,7,18,19,20,21,22]. To qualify as a biological state variable, such organization must persist long enough to be modified by biological fluids or interrogated by enzymes, receptors, or cells [7,21,22]. Transient molecular fluctuations that do not persist on a biologically relevant sampling timescale are not treated here as state variables.

Source–state association can arise through at least two mechanistically distinct routes. Material continuity occurs when lipids derived from a source membrane are directly transferred into a nascent extracellular interface, as during ABCA1-dependent efflux of cellular phospholipids and free cholesterol to apoA-I in nascent high-density lipoprotein formation [23]. Configurational continuity, as defined here, does not require physical retention of a pre-existing membrane patch. In apoB-containing systems, hepatic or intestinal metabolic state can alter lipid-substrate availability, neutral-lipid loading, microsomal triglyceride transfer protein-dependent lipidation, intracellular particle assembly, and presecretory oxidative processing [24,25,26,27]. These source-dependent biases may consequently be reflected in the composition and interfacial organization of newly secreted particles. Both routes are compatible with source-associated particle states, but they represent different mechanisms and should not be conflated experimentally.

For clarity, extracellular lipid-state exchange is used here solely as a descriptive process term for the sequence by which source-associated lipid organization is assembled de novo or transferred into a particle, subsequently remodeled in biological fluids, and ultimately interrogated by recipient-cell receptors, membranes, or uptake pathways [3,4,7,23,24,25,26,27]. It is neither proposed as a new particle taxonomy nor advanced as the principal conceptual claim of this article. Molecular transfer of individual lipids among membranes, apolipoproteins, and lipoprotein particles is established background biology [4,23], but such transfer alone does not demonstrate a state-dependent mechanism. Within the present framework, lipid exchange becomes mechanistically relevant only when it generates, preserves, or modifies a persistent interface state, or produces a reproducible functional consequence that cannot be explained solely by the quantity or molecular identity of the lipid species transferred.

2.2. Scaffold-Interface Coupling and Particle Identity

The central hypothesis is that coupling between lipid-interface state and an apolipoprotein scaffold helps determine the biologically operative identity of a lipoprotein. The lipid surface provides a physically accessible but potentially variable interfacial substrate, whereas apolipoprotein scaffolds stabilize particular lipid assemblies, influence the structural and remodeling transitions available to them, and link particle organization to enzymatic and receptor-mediated routing [6,7,18,20,28]. The proposed sequence is: source-state bias → lipid loading or transfer → particle assembly and apolipoprotein scaffolding → remodeling in biological fluids → recipient-cell routing and response [3,4,23,24,25,26,27]. This sequence is presented as a testable model, not as an assertion that every established process in lipoprotein metabolism already demonstrates state-dependent causality.

Apolipoproteins are interpreted here as biogenetic scaffold, in addition to their established structural, enzymatic, and receptor-binding roles. In apoB-containing particles, cotranslational association of apoB with microsomal triglyceride transfer protein couples phospholipid and neutral-lipid recruitment to particle assembly and secretion [24,25,29]. Because apoB is non-exchangeable and remains structurally integrated as triglyceride-rich particles undergo intravascular remodeling, this branch is relatively scaffold-continuous: perturbation of apoB or microsomal triglyceride transfer protein can impair particle formation and secretion and alter subsequent particle composition and metabolic fate [3,24,25,29]. In the high-density lipoprotein branch, apoA-I and other exchangeable apolipoproteins form more adaptable scaffolds; ATP-binding cassette transporter A1 initiates their lipidation, whereas lecithin–cholesterol acyltransferase and other plasma remodeling factors drive subsequent changes in particle size, composition, morphology, and metabolic interactions [4,7,23,28,30,31]. The two branches therefore instantiate the same scaffold–interface principle under different degrees of scaffold continuity and structural constraint.

The biogenetic scaffold must be distinguished from a subsequently editable, editable identity layer. ApoB incorporated during intracellular assembly, or apoA-I engaged during nascent HDL biogenesis, belongs to the biogenetic scaffold that establishes continuity with the particle’s assembly pathway [24,29,30,31]. Once particles enter the extracellular compartment, exchangeable apolipoproteins, lipid-transfer and remodeling proteins, acute-phase proteins, clusterin, and selected complement- and protease-regulatory proteins can associate with, dissociate from, or redistribute among mature particles [4,7,9,15,32,33]. These dynamically associated components are interpreted here as an editable identity layer that may alter interfacial accessibility, structural stability, enzymatic remodeling, receptor interactions, and clearance. The distinction prevents constitutive or biogenetically incorporated scaffold proteins from being merged indiscriminately with proteins that associate with particles during subsequent extracellular remodeling.

2.3. Fluid-Phase Editing and Recipient-Cell Interpretation

Within this framework, particle identity is neither fully specified by lipid composition nor fixed at biogenesis. Interfacial organization can influence the binding, retention, and conformation of exchangeable apolipoproteins and remodeling proteins, whereas dynamically associated proteins can in turn alter the exposure and accessibility of interfacial sites, regulate enzyme access, catalyze lipid remodeling, and modify receptor-mediated clearance [4,7,28,34,35,36]. The model therefore posits reciprocal causality: interface state biases protein association, while protein association feeds back on interface accessibility, organization, and remodeling. This protein–lipid cooperativity, rather than either component considered alone, constitutes the central mechanistic unit of the hypothesis.

Biological specificity is hypothesized to emerge from combinatorial recognition rather than from any single molecular feature. Neither the presence of an oxidized phospholipid, increased interfacial anionic character, apoE enrichment, nor complement association is expected to function as a universal biological code, because the consequences of each feature depend on its molecular presentation, protein context, remodeling state, and the receptors expressed by the responding cell [10,18,37,38,39,40]. The relevant mechanistic unit is therefore the coupled particle state: the combination of lipid-interface organization, the biogenetic scaffold, the editable identity layer, component stoichiometry, temporal persistence, remodeling history, and recipient-cell context. The same interfacial lipid feature may consequently produce different outcomes when presented on particles with different biogenetic scaffold—for example, apoB- versus apoA-I-scaffolded particles—or within different acquired protein environments, such as apoE-enriched or complement-enriched identity layers. This context dependence is a testable prediction of the model rather than an assertion that all listed combinations have already been experimentally demonstrated.

Recipient cells interrogate the coupled particle state through established receptor and uptake systems, including LDL receptor-family pathways, scavenger receptors, scavenger receptor class B type I-mediated selective lipid transfer, complement-assisted recognition, and endocytic or systemic clearance pathways [3,36,37,41,42]. Particle uptake alone does not demonstrate a state-coupled mechanism, because altered uptake can result from differences in particle abundance, bulk cargo, or nonspecific internalization. Evidence for state coupling requires a reproducible relationship among a defined interfacial feature, a defined scaffold or identity-layer configuration, and a defined downstream response—such as altered receptor dependence, intracellular trafficking, endothelial activation, inflammatory output, or clearance kinetics—under conditions that control for particle number, bulk lipid content, and major apolipoprotein abundance [36,37,43].

2.4. Predictions and Boundaries

The primary prediction is that particles matched as closely as possible for conventional variables—including particle number, size, bulk lipid content, and major apolipoprotein abundance—can nevertheless differ in stability, remodeling, routing, or biological activity when their lipid-interface states differ [10,34,35,36,44]. A second prediction is that apoB-containing particles will exhibit greater scaffold continuity and lower scaffold exchangeability than HDL-related particles [7,24,29,30,31]. A third is that, after exposure to the same biological fluid, the composition and residence of particle-associated proteins will be partly constrained by interfacial curvature, lipid packing, oxidative modification, electrostatic character, and cholesterol accessibility [18,20,34,35]. A fourth is that disease-relevant routing and responses will depend on interactions between interface state and scaffold or identity-layer configuration, rather than on any single lipid or protein feature considered in isolation [36,37,38,39,40,43,44]. These predictions require controlled perturbation and matched-particle comparisons; they are not inferred merely from correlations among particle composition, protein association, and function.

The hypothesis further predicts temporal state ordering rather than a simple abundance–response relationship. A pre-existing hepatic, metabolic, or inflammatory state is expected to bias the coupled particle states generated in response to a standardized challenge and their subsequent extracellular remodeling [15,27,45,46]. Consequently, two systems exposed to the same challenge may generate similar particle abundances yet diverge in interfacial organization, associated-protein configuration, remodeling kinetics, routing, and function. Putative early source-associated features should be considered mechanistically informative only if they are detectable before overt tissue injury, remain after exclusion of ex vivo oxidation and nonspecific release from damaged cells or membrane fragments, and prospectively predict—or, when selectively perturbed, causally alter—later particle remodeling, routing, or biological activity. These temporal and artifact-control requirements distinguish state ordering from a secondary consequence of tissue injury.

The scope boundaries are deliberately strict. Oxidized low-density lipoprotein, dysfunctional high-density lipoprotein, lipoprotein-X, and reported lipoprotein–extracellular-vesicle co-isolates or complexes should continue to be interpreted within their established mechanistic and methodological frameworks whenever those frameworks adequately account for the observed particle properties and biological effects [11,16,17,37,39,47,48]. The present hypothesis is restricted to established lipoprotein systems and does not posit any non-classical category of extracellular particles. If particle abundance and size, bulk lipid composition, apolipoprotein composition, established enzymatic and receptor pathways, and clearance kinetics fully account for an observation, the proposed scaffold–interface layer should not be invoked, because it provides no additional explanatory or predictive gain.

3. Evaluation of the Hypothesis/Idea

3.1. Evidence Consistent with the Hypothesis

The physical architecture of lipoproteins supports viewing them as protein-stabilized lipid interfaces. Each human low-density lipoprotein particle contains a single apoB100 molecule whose architecture includes a large globular N-terminal domain and an approximately 61-nm continuous amphipathic β-sheet belt that encircles the particle surface, providing a structural basis for strong scaffold continuity during the metabolic conversion of very-low-density lipoprotein to intermediate-density lipoprotein and low-density lipoprotein [29,49]. In mice lacking intestinal apoB expression, apoB-free, chylomicron-sized triglyceride-rich particles were detected within the endoplasmic reticulum lumen, but they were less abundant and rarely reached the Golgi apparatus or extracellular compartment [50]. Complementary studies showed that these animals failed to form and secrete normal chylomicrons and exhibited profound defects in intestinal lipid transport [51]. These observations do not imply that physiological chylomicrons exist independently of apoB. Rather, they support the narrower inference that formation of an apoB-free, neutral-lipid-rich physical substrate within the endoplasmic reticulum can be partially separable from apoB-dependent particle maturation, endoplasmic-reticulum-to-Golgi transport, secretion, and subsequent biological routing.

The HDL branch provides complementary evidence for a more dynamic scaffold–interface relationship. ABCA1 promotes the transfer of cellular phospholipids and free cholesterol to extracellular, lipid-poor apoA-I, thereby generating heterogeneous nascent HDL particles [23,31]. Nascent HDL particles can differ in apoA-I stoichiometry, size, and lipid composition, whereas mature HDL subclasses additionally differ in lipidome, associated proteome, structural stability, remodeling behavior, and biological function [7,8,9,10,31]. Exchangeable apolipoproteins contain amphipathic α-helices that bind lipid–water interfaces and undergo lipid-sensitive conformational rearrangements, allowing apoA-I to accommodate particles of different dimensions and compositions [28,34]. More generally, certain amphipathic helices can preferentially associate with curved, defect-rich lipid interfaces, providing a biophysical precedent for coupling between interfacial packing and protein organization, although this specific sensing mechanism has not yet been established as a general property of HDL apolipoproteins [18]. Together, these observations are consistent with—but do not by themselves prove—a dynamic HDL scaffold whose conformation, exchangeability, and associated-protein configuration are coupled to interfacial organization.

Pathological particles and analytically overlapping particle populations provide useful boundary cases. Lipoprotein-X is enriched in phospholipids and unesterified cholesterol, lacks apoB, and can be misclassified within or interfere with routine LDL cholesterol measurements in cholestatic conditions [16,17,52]. It demonstrates that disease can generate an abnormal but already recognized extracellular lipid-particle organization without requiring the proposal of an unknown particle category. Low-density lipoproteins can also co-purify with and mimic extracellular vesicles during isolation and detection, and association between LDL and isolated extracellular vesicles has been observed after in vitro mixing [47,48]. These cases illustrate why state-resolved analysis is informative only when biological particle identity is distinguished from operational fractionation, analytical similarity, and ex vivo association.

Synthetic lipid nanoparticles provide a useful reverse-engineering analogy. Upon exposure to biological fluids, they acquire biomolecular coronas containing apolipoproteins, lipids, and other plasma components. In specific mRNA–lipid-nanoparticle systems, HDL-enriched or HDL-derived corona components were required for efficient productive delivery, altered receptor dependence, and enhanced hepatic protein expression [53]. ApoE binding can also induce redistribution of surface and core lipids, remodel internal particle structure, and promote partial release of encapsulated mRNA [54]. Synthetic particles are not endogenous lipoproteins, and their corona biology should not be treated as direct evidence for an endogenous lipoprotein mechanism. They nevertheless provide a controlled demonstration that a lipid-containing interface can selectively acquire a protein environment that modifies particle structure, cellular uptake pathways, biodistribution, and functional delivery [53,54]. Complementary evidence comes from human experimental endotoxemia: acute inflammatory remodeling enriched HDL in serum amyloid A proteins and impaired macrophage cholesterol-efflux capacity despite unchanged HDL cholesterol concentrations [55]. This finding does not establish a lipid-interface-state mechanism, but it demonstrates that protein remodeling can alter lipoprotein function in ways not represented by a conventional bulk concentration measurement.

Together, these observations support the plausibility of scaffold continuity across assembly and remodeling, protein–lipid cooperativity, and fluid-phase editing. They do not establish that a defined interface state systematically predicts function after conventional particle variables have been controlled. That incremental causal proposition remains the distinctive and testable part of the hypothesis.

3.2. Alternative Explanations and Limitations

Several alternative explanations could render the proposed terminology unnecessary. Differences attributed to lipid-interface state may already be fully explained by particle number and size, bulk lipid composition, apolipoprotein composition, or established lipoprotein subclasses and modification pathways. Any residual association with an apparent interface feature may instead reflect an incompletely measured conventional variable or a correlated consequence of particle damage. Candidate state dimensions are also strongly coupled: oxidation can simultaneously alter lipid and apoB chemistry, interfacial organization and charge, aggregation propensity, protein association, and receptor recognition [6,37,39,56]. Consequently, observational association—or even a broad oxidative perturbation—cannot identify which interface variable is causally responsible. Causal assignment requires matched-particle comparisons and selective or orthogonal perturbations that alter the candidate feature while controlling major covariates, ideally accompanied by reversal, rescue, or mediation evidence linking that feature to the downstream response.

No single measurement directly and comprehensively resolves the lipid-interface state of an intact lipoprotein particle. Lipidomics defines molecular composition and modification but does not by itself determine supramolecular organization, topological exposure, packing, hydration, phase behavior, or molecular accessibility [8]. Environment-sensitive probes, enzyme- or probe-accessibility assays, scattering and imaging methods, and protein-conformation measurements each interrogate different spatial, temporal, or molecular aspects of the interface; even measurements nominally described as lipid order can yield non-equivalent or conflicting readouts [34,49,57,58]. Sample isolation and handling introduce additional risks. Density ultracentrifugation can shed or redistribute exchangeable apolipoproteins and alter particle composition, prolonged or insufficiently protected processing can permit ex vivo lipid oxidation, and density- or size-based fractionation can co-isolate lipoproteins with extracellular vesicles [47,48,59,60,61]. Strong inference therefore requires convergence across orthogonal measurements, comparison of more than one isolation strategy where feasible, and explicit particle-integrity and artifact controls rather than treating any single analytical proxy as the state itself.

Finally, the hypothesis is vulnerable to conceptual overextension. If every compositional change, chemical modification, aggregation event, or alteration in protein association is relabeled as a particle-state effect, the terminology provides no additional explanatory value. The model is meaningful only when it identifies a reproducible mechanistic sequence linking a defined and selectively perturbable interfacial feature to a defined change in scaffold conformation or identity-layer configuration and, subsequently, to a distinct routing or response pattern under appropriately matched particle conditions. Increased uptake of damaged, aggregated, or complement-opsonized particles is insufficient by itself, because such behavior may already be explained by established scavenger-receptor, complement-assisted, or nonspecific clearance pathways [37,39,42,56]. Support for a state-coupled mechanism therefore requires incremental explanatory or predictive information beyond these conventional damage-recognition pathways, ideally together with selective perturbation, reversal, or rescue of the proposed interface-dependent sequence.

4. Hypothesis Testing

The first strategy is matched-particle reconstruction or controlled interfacial editing. In the HDL branch, apoA-I-scaffolded reconstituted particles can be generated with closely matched size, scaffold stoichiometry, and total lipid content while varying a prespecified interfacial feature [44,62]. In the apoB branch, native or cell-generated apoB-containing particles should be subjected to controlled surface editing or produced under matched biogenetic conditions, because the non-exchangeable apoB scaffold is integrated during intracellular particle assembly [24,29,49]. Candidate perturbations include the abundance and surface presentation of defined oxidized phospholipids, lysophospholipid content, ceramide-to-sphingomyelin balance, cholesterol accessibility, or exposure of anionic lipids. Composition-changing experiments can establish lipid-component effects, but a stronger test of interface state requires particles with identical or closely matched molecular composition that differ in packing, accessibility, topology, or assembly history. After exposure to the same defined biological fluid or protein mixture, particle-associated protein composition, stoichiometry and residence, structural stability, complement association, receptor dependence, uptake, and cellular responses should be compared [35,42,53,54]. The strongest evidence would be a reproducible functional difference that tracks with the defined interfacial perturbation after control of particle number, size, bulk composition, and scaffold abundance, and that is abolished or reversed when the interface state is normalized.

The second strategy tests source-state continuity. Hepatocyte or enterocyte models should be exposed to defined metabolic, oxidative, or inflammatory perturbations, followed by collection of newly secreted apoB-containing particles under standardized conditions [24,25,26,27,63,64]. Because these perturbations may alter secretion rate, particle size, and bulk composition, comparisons should match or adjust for particle number, apoB molarity, size distribution, major lipid classes, and relevant exchangeable apolipoproteins, while excluding carryover of cytokines, metabolites, cell debris, and membrane fragments. The key question is whether the source perturbation generates a reproducible interfacial and identity-layer phenotype that persists after these controls and can be phenocopied by controlled lipid loading or interfacial editing. In parallel, ABCA1-mediated lipidation of apoA-I can test the more direct material-continuity route, ideally by tracing labeled cellular phospholipids or cholesterol into nascent HDL [23,31]. Together, these experiments distinguish configurational continuity established during intracellular apoB-particle assembly from material continuity produced by direct transfer of source-membrane lipids to extracellular apoA-I.

The third strategy tests the separation between the biogenetic scaffold and the editable identity layer. Perturbations of apoB during apoB-particle assembly, or of apoA-I during nascent HDL formation, test the establishment of the particle scaffold, whereas interventions targeting microsomal triglyceride transfer protein or ATP-binding cassette transporter A1 test the intracellular assembly or initial lipidation pathways through which that scaffold is generated [23,24,29,30,31]. These biogenetic interventions should be distinguished from post-formation editing of otherwise matched particles by controlled exposure to exchangeable apolipoproteins such as apoE or apoC-III, clusterin, selected complement components or regulators, and defined lipid-transfer or remodeling enzymes [4,32,35,36,42]. Albumin may be included as a high-abundance fluid-phase comparator, but should not be assigned to the identity layer without demonstrating stable particle association and a specific functional effect. Measurements should include particle integrity, interfacial organization, protein stoichiometry and residence, receptor dependence, and reversal or rescue. Support would be strongest when particles retaining the same biogenetic scaffold acquire different routing or functional behavior after a selective identity-layer perturbation, and when the magnitude or composition of that protein acquisition is itself altered by a prespecified interface state.

The fourth strategy maps recipient-cell interpretation. Closely matched particles should be compared across hepatocytes, endothelial cells, macrophages, and isogenic or otherwise defined receptor systems [3,36,37,41,42,43]. Total cellular uptake alone is not decisive, because it does not distinguish surface binding, selective lipid transfer, whole-particle internalization, intracellular trafficking, degradation, or nonspecific clearance. A stronger test asks whether a prespecified interfacial feature, in combination with a defined scaffold or identity-layer configuration, generates a reproducible downstream pattern—such as altered receptor dependence, intracellular routing, cytokine output, endothelial activation or barrier function, or clearance kinetics—after control of particle number, size, bulk lipid content, and major apolipoprotein abundance. Receptor blockade or genetic deletion should identify the responsible recognition pathway, whereas normalization of the interface state or selective removal and reconstitution of the identity-layer component should abolish and restore the response, respectively. Such experiments can distinguish generic uptake of damaged or opsonized material from a specific coupled-state response.

A complementary longitudinal strategy should characterize particle trajectories at predefined phases encompassing baseline, early remodeling, peak response, and recovery during a standardized inflammatory or metabolic perturbation [45,55]. At each phase, particle number and size, conventional lipid measures, major apolipoproteins, lipidomic and proteomic profiles, interface-sensitive measurements, systemic inflammatory variables, and indices of tissue injury should be assessed in parallel. The model would gain support if an early coupled particle state prospectively predicts subsequent remodeling, routing, recovery, or biological function and provides incremental predictive information beyond challenge exposure, cytokine concentrations, particle abundance, conventional lipid variables, and tissue-injury burden. This should be tested by comparing prespecified models with and without the state-resolved variables, preferably using independent validation or appropriately cross-validated longitudinal analyses. No single observational or perturbational experiment is sufficient. Support requires convergence among controlled interface perturbation, scaffold or identity-layer analysis, evidence of structural persistence, temporal precedence, and a downstream response that cannot be reduced to particle amount, bulk composition, residual stimulus, or nonspecific tissue damage (Table 1).

5. Consequences of the Hypothesis and Discussion

If confirmed, the hypothesis would add a state-resolved mechanistic layer to lipoprotein biology without replacing its established taxonomy or conventional clinical variables. Routine measurements of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides would remain fundamental, while apoB, apoA-I, and direct particle-number measurements would continue to provide additional information where clinically or experimentally appropriate [14]. Interface-sensitive and identity-layer measurements would be justified only if they provide reproducible mechanistic or predictive information beyond these established variables—for example, when particles with closely matched conventional profiles exhibit different remodeling, routing, or biological activity [12,13,55]. The resulting candidate biomarker would therefore not be an isolated lipid species or protein concentration, but a validated multivariable signature integrating interfacial organization, scaffold and identity-layer configuration, temporal persistence, and functional trajectory.

Inflammation provides a directly relevant clinical test case. In human experimental endotoxemia, acute remodeling of the HDL proteome impaired macrophage cholesterol-efflux capacity despite unchanged HDL-cholesterol concentrations, demonstrating that a conventional concentration measure can miss an acute change in particle function [55]. The hypothesis predicts that combining interface-sensitive measurements with identity-layer remodeling will better distinguish prospectively defined adaptive and maladaptive particle trajectories—for example, preserved versus impaired efflux, resolving versus persistent inflammatory activity, or normalized versus delayed clearance. In cholestasis, lipoprotein-X provides an established boundary case in which abnormal lipid organization and protein composition complicate interpretation by routine lipoprotein classification and low-density-lipoprotein-cholesterol measurements [16,17,52]. In cardiometabolic disease, established evidence already shows that HDL function is not fully represented by HDL cholesterol or apoA-I concentration and that exchangeable surface apolipoproteins can modify receptor-dependent clearance of apoB-containing particles [12,13,36]. The further prediction is that particles with closely matched apoB concentration, HDL cholesterol, or other conventional profiles may differ in routing, inflammatory activity, or clearance because their coupled interface–protein states differ. These applications must first be tested within established lipoprotein pathways; novelty is justified only when state-resolved variables provide reproducible causal or predictive information beyond conventional measurements and known mechanisms.

The model may also provide a mechanistic bridge between endogenous lipoprotein biology and drug-delivery science. After exposure to biological fluids, synthetic lipid nanoparticles can acquire dynamic biomolecular coronas containing apolipoproteins and other fluid-phase components, and this acquired environment can alter particle structure, receptor dependence, cellular uptake, biodistribution, and productive cargo delivery [21,22,53,54]. Defining how lipid-interface organization constrains corona acquisition and subsequent particle remodeling could therefore inform more predictive carrier-design principles. Conversely, endogenous lipoproteins provide naturally occurring examples of protein-scaffolded lipid interfaces whose assembly, structural stability, extracellular remodeling, and receptor routing are biologically regulated [29,31]. The analogy is mechanistic rather than taxonomic: synthetic lipid nanoparticles are not treated as lipoproteins, and endogenous lipoproteins are not reduced to synthetic nanoparticles with protein coronas.

A major consequence of this framework is methodological restraint. The concept should not be used merely to relabel every modified lipoprotein, extracellular vesicle, lipoprotein–vesicle co-isolate, or analytically abnormal fraction as a distinct particle state [11,16,17,47,48,56]. Reproducible qualitative divergence in receptor dependence, intracellular routing, remodeling behavior, signaling pattern, or clearance is more informative than a small residual difference that can plausibly be attributed to incomplete matching, measurement error, particle damage, or unmeasured conventional covariates. If the observed behavior is adequately explained by particle abundance and size, bulk lipid and apolipoprotein composition, established modification pathways, known receptors, remodeling enzymes, or clearance mechanisms, scaffold–interface coupling provides no necessary incremental explanation. In such cases, the observation should remain within conventional lipoprotein biology rather than being redescribed in state-resolved terminology.

6. Conclusions

Classical lipoproteins can be investigated as apolipoprotein-scaffolded lipid-state particles in which interfacial organization and protein scaffolding are dynamically coupled. ApoB-containing systems are predicted to exhibit strong scaffold continuity and low scaffold exchangeability, whereas HDL-related systems operate through more adaptable and exchangeable apolipoprotein scaffolds. Subsequent association with fluid-phase proteins and remodeling enzymes can further modify particle stability, interfacial accessibility, metabolic routing, and biological function.

The proposal does not assume that ordinary molecular lipid transport, compositional heterogeneity, or every modification of a lipoprotein represents a state-dependent mechanism. It stands or falls on a practical and falsifiable question: when particle number, size, bulk lipid composition, total lipid mass, major scaffold abundance, and established receptor pathways are appropriately matched or controlled, does selective alteration of lipid-interface organization reproducibly change protein acquisition, remodeling, routing, or recipient-cell response?

A positive answer would justify a state-resolved mechanistic extension of established lipoprotein biology. A negative answer—or evidence that the observed variation is fully explained by conventional composition, apolipoprotein configuration, enzymatic remodeling, receptor recognition, or clearance pathways—would return those observations to established lipoprotein models.

Declaration of generative AI and AI-Assisted Technologies in the Manuscript Preparation Process: During the preparation of this work, the author used ChatGPT 5.6 for language refinement, formatting assistance, and logical proofreading. After using this tool, the author reviewed and edited the content as needed and takes full responsibility for the content of the published article.